Diabetes, heart risk lower with newer antipsychotic

	Tweet

In a study of schizophrenic patients, those treated with the newer antipsychotic drug Abilify had more favorable changes in metabolic parameters such as blood sugar, lipids and body weight, compared to those receiving older “standard of care” agents.

This translates into a reduced risk of diabetes and heart disease in Abilify-treated patients, researchers report. Abilify, which is also called aripiprazole, is a second-generation “atypical” antipsychotic agent.

“Patients with schizophrenia are at increased risk of developing diabetes mellitus and cardiovascular disease,” Dr. Hong J. Kan, of Bristol-Myers Squibb Co., Wallingford, Connecticut, and colleagues note in the Journal of Clinical Psychiatry. “Furthermore, some atypical antipsychotics are associated with metabolic disturbances, which augment the risk for these comorbid conditions.”

Results of the Schizophrenia Trial of Aripiprazole, or STAR, study, demonstrated that aripiprazole was comparable or superior to “standard of care” drugs (quetiapine, olanzapine, or risperidone) depending on the outcome measure.

In a post hoc analysis of the metabolic data collected in the study, Kan and colleagues observed more favorable changes in blood fats (lipids), blood sugar, and body weight in patients treated with aripiprazole compared with those treated with the other agents.

One model predicted 23.4 fewer instances of new cases of diabetes with aripiprazole versus the older drugs. Another “hypothetical” model predicted 3.9 fewer heart disease-related events with aripiprazole versus the older drugs.

“Treatment with aripiprazole provides similar efficacy relative to other antipsychotic agents, and, in addition, its favorable metabolic profile offers potential health benefits,” Kan and colleagues conclude.

SOURCE: Journal of Clinical Psychiatry, May 2008.

RELATED STORIES:
Phone contact with nurses linked with better outcomes for women with gestational diabetes   Death rate drops among Americans with diabetes -CDC   Correct treatment of common diabetic foot infections can reduce amputations   “Pre-diabetes,” diabetes rising among U.S. teens   Experimental bariatric surgery controls blood sugar in rats with diabetes   53 millions Americans might develop diabetes by 2025   New inflammation hormone link may pave way to study new drugs for type 2 diabetes   Diabetic retinopathy research could reduce screening costs   Liver fat gets a wake-up call that maintains blood sugar levels   Low testosterone levels could raise diabetes risk for men   Prosthetic lets diabetic get a foot up on life   Dealing with Diabetes, One Patient at a Time

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]